Masato Katagiri Selected Research

amrubicin

1/2020	Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
10/2018	Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
1/2018	Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
1/2018	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
3/2017	Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.
8/2015	Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
6/2012	Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
10/2010	Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.
9/2009	Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.
3/2007	Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masato Katagiri Research Topics

Disease

23	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2020 - 08/2005
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 09/2009
4	Neoplasms (Cancer) 11/2018 - 02/2003
2	Neoplasm Metastasis (Metastasis) 10/2019 - 11/2018
2	Disease Progression 01/2019 - 01/2019
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2018 - 01/2015
2	Adenocarcinoma of Lung 11/2018 - 03/2010
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018 - 11/2016
2	Diabetes Mellitus 01/2018 - 04/2013
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018 - 03/2010
2	Venous Thromboembolism 01/2018 - 11/2016
2	Hypercapnia 12/2016 - 01/2015
2	Lung Neoplasms (Lung Cancer) 01/2012 - 12/2008
1	COVID-19 05/2022
1	Acute Kidney Injury (Acute Renal Failure) 03/2022
1	Kidney Diseases (Kidney Disease) 03/2022
1	Necrotizing Pneumonia 07/2021
1	Brain Neoplasms (Brain Tumor) 12/2020
1	Radiation Pneumonitis 01/2020
1	Albuminuria 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018
1	Vascular Diseases (Vascular Disease) 01/2018
1	Erysipelas 08/2015
1	Leukopenia 08/2015
1	Infections 08/2015
1	Eosinophilia 03/2015
1	Sepsis (Septicemia) 01/2015
1	Asthma (Bronchial Asthma) 01/2015
1	Neutropenia 06/2012
1	Diarrhea 03/2010
1	Exanthema (Rash) 03/2010
1	Carcinoma (Carcinomatosis) 09/2009
1	Hyperglycemia 06/2006

Drug/Important Bio-Agent (IBA)

10	amrubicinIBA 01/2020 - 03/2007
8	ErbB Receptors (EGF Receptor)IBA 01/2020 - 08/2005
5	Pharmaceutical PreparationsIBA 12/2020 - 08/2005
5	Tyrosine Kinase InhibitorsIBA 01/2020 - 03/2010
5	Gefitinib (Iressa)FDA Link 01/2015 - 08/2005
3	PlatinumIBA 01/2018 - 08/2005
3	Pemetrexed (MTA)FDA Link 01/2016 - 01/2012
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2015 - 03/2010
3	Irinotecan (Camptosar)FDA LinkGeneric 06/2012 - 03/2007
2	osimertinibIBA 01/2019 - 01/2019
2	NivolumabIBA 01/2019 - 11/2018
2	130-nm albumin-bound paclitaxelIBA 01/2018 - 01/2018
2	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 01/2018
2	Aminophylline (Carine)FDA LinkGeneric 12/2016 - 01/2015
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2013 - 06/2006
1	Glucose (Dextrose)FDA LinkGeneric 05/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 05/2022
1	Blood Glucose (Blood Sugar)IBA 05/2022
1	bardoxolone methylIBA 03/2022
1	Panton-Valentine leukocidinIBA 07/2021
1	AfatinibIBA 12/2020
1	durvalumabIBA 01/2020
1	Zoledronic Acid (Zometa)FDA Link 10/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Carbon MonoxideIBA 12/2018
1	Immune Checkpoint InhibitorsIBA 11/2018
1	B7-H1 AntigenIBA 11/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	CollagenIBA 01/2018
1	nedaplatinIBA 01/2018
1	Low Density Lipoprotein Receptor-Related Protein-2IBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Etoposide (VP 16)FDA LinkGeneric 01/2018
1	AsbestosIBA 01/2018
1	Oxidants (Oxidizing Agents)IBA 01/2018
1	Immunoglobulin E (IgE)IBA 03/2015
1	Theophylline (Theon)FDA LinkGeneric 01/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015
1	Tyrosine (L-Tyrosine)FDA Link 04/2013
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 04/2013
1	Enalapril FDA LinkGeneric 04/2013
1	Topoisomerase II InhibitorsIBA 06/2012
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2012
1	Topoisomerase I InhibitorsIBA 06/2012
1	Docetaxel (Taxotere)FDA Link 01/2012
1	Phosphotransferases (Kinase)IBA 03/2010
1	Biological ProductsIBA 09/2009
1	Warfarin (Coumadin)FDA LinkGeneric 08/2009
1	Peptide Nucleic AcidsIBA 12/2008
1	3-nitrotyrosineIBA 06/2006
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2005
1	anilinoquinazolineIBA 08/2005
1	von Willebrand FactorIBA 02/2003

Therapy/Procedure

10	Drug Therapy (Chemotherapy) 01/2020 - 08/2005
8	Therapeutics 05/2022 - 01/2012
2	Chemoradiotherapy 01/2020 - 07/2017
2	Surgical Casts (Plaster Cast) 01/2018 - 11/2016
1	Drug Tapering 12/2020
1	Immunotherapy 01/2017